#Denmark #Copenhagen #Alzheimer's #Muna Therapeutics #TREM2 signaling

Muna Therapeutics Validates Microglial State Transitions in Alzheimer's Research

Muna Therapeutics, a pioneering clinical-stage biotechnology firm, has made a monumental stride in understanding Alzheimer's disease, evidenced by their recent publication in Nature Medicine. Titled "Human microglial transitions at the Aβ–Tau inflection point associate with divergent pathways to dementia and resilience," this study redefines how we perceive the chronic neurodegenerative disorder.

In collaboration with renowned research institutions across Belgium, the Netherlands, and the UK, Muna harnessed its innovative MiND-MAP platform to meticulously analyze the mechanisms behind cognitive resilience in the face of Alzheimer's-related brain pathology. Their findings highlight that the progression of Alzheimer's is not solely determined by the accumulation of toxic proteins such as amyloid and tau, but critically influenced by the response of microglia— the brain's immune cells— to these pathological changes.

A key revelation from the study is the identification of a pivotal "tipping point" in microglial behavior, transitioning from a protective, inflammatory state to a more detrimental state associated with neurodegeneration. This shift is particularly linked with tau pathology, which poses serious threats to cognitive health. Importantly, the early protective stage of microglial activity is enriched in TREM2 signaling, a pathway Muna is currently targeting with its clinical candidate, MNA-001, a promising small molecule designed for oral administration.

Dr. Niels Plath, Chief Scientific Officer at Muna, underscores the significance of these findings, stating, "This study suggests that the switch from amyloid to tau pathology isn’t a fixed outcome, but rather a modifiable process that can be influenced by interventions targeting microglial transitions and TREM2 pathways." This perspective is crucial in the broader context of treatment strategies for Alzheimer’s disease and other related neurodegenerative conditions.

The implications of this research extend beyond mere academic interest. The study showcased that cognitively healthy individuals, including centenarians, maintain their cognitive functions by either avoiding detrimental microglial transitions or dissociating microglial activation from the accumulation of tau. By uncovering these mechanisms, Muna is positioning itself at the forefront of therapeutic advancements aimed at promoting cognitive health.

CEO Rita Balice-Gordon remarked, "This publication in Nature Medicine emphasizes the incredible potential of our MiND-MAP technology to unravel intricate cellular mechanisms behind Alzheimer’s disease. It reinforces our method of leveraging TREM2 agonism to bolster the brain's natural defense systems. Our upcoming clinical trials with MNA-001 will be grounded on these high-resolution findings that aim to disrupt harmful neuroinflammatory cycles, maintaining cognitive integrity and paving the way for innovative Alzheimer’s treatments in the future."*

Muna Therapeutics is at the cusp of a new frontier in drug discovery for neurodegenerative diseases. By enhancing brain resilience against the debilitating impacts of misfolded proteins, they aim to safeguard cognitive functions. The company's name, derived from Old Norse meaning 'to remember', perfectly encapsulates its mission to develop therapeutic candidates capable of halting or reversing the effects of diseases like Alzheimer's.

For more details on Muna’s groundbreaking research and future endeavors, visit the Muna Therapeutics website.

This pioneering work is not just a milestone for Muna Therapeutics; it could redefine how we approach treatments for Alzheimer's and other neurodegenerative diseases moving forward.